A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours

Malignant Solid Tumor Clinical Trial

Official title:

A Safety, Tolerability and Pharmacokinetic Dose Escalation and Expansion, Phase I/Ib Study of AMC303 as Monotherapy in Patients With Advanced or Metastatic, Malignant Solid Tumour of Epithelial Origin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03009214
• Other study ID #: AMC303-01
• Status: Completed
• Phase: Phase 1
• Start date: December 2016
• Est. completion date: May 7, 2021

Study information

• Verified date: May 2021
• Source: amcure GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a two part Phase I/Ib, open-label, non-randomized and multi-center, dose escalation study with a 3+3 design (Part 1) and an expansion cohort at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) (Part 2). If MTD is not reached in Part 1, RP2D will be determined after completion of Part 1 considering safety and tolerability, also beyond the dose limiting toxicity (DLT) period, pharmacokinetic (PK) and pharmacodynamic (PD) results.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: May 7, 2021
• Est. primary completion date: July 28, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed and documented, advanced or metastatic, accessible malignant solid tumour of epithelial origin and for which no standard therapy exists or standard therapy has failed.

2. Presence of a measurable tumour according to RECIST 1.1. criteria

3. At least 4 weeks from the completion of any previous cytotoxic chemotherapy, 6 weeks from biological therapy (monoclonal antibodies) or cancer immunotherapy (immune checkpoint modulators) or 2 weeks from targeted therapy (receptor tyrosine kinase inhibitors) at time of administration of AMC303.

4. Male or female patients, at least 18 years of age

5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1

6. Life expectancy > 12 weeks.

7. Adequate haematological function defined as

• Absolute neutrophil count (ANC) > 1,500 / µL

• Platelets > 100,000 / µL

• Haemoglobin > 9 g /dL.

8. Adequate renal function defined as

• Glomerular filtration rate (GFR) = 50 ml/min according to local laboratory standard or

• Serum creatinine < 1.5 mg / dL.

9. Adequate hepatic function defined as

• Total bilirubin < 1.5x institutional upper limit of normal (ULN)

• AST, ALT = 3x institutional ULN or < 5x institutional ULN if known hepatic metastases

• Alkaline phosphatase < 3x institutional ULN or < 5x institutional ULN if known hepatic metastases.

10. Patient may have central nervous system (CNS) involvement if metastases have been treated and are stable at least 4 weeks after completion of radiation therapy and/or surgery. Stable disease is defined as absence of new neurological symptoms, absence of the need for steroid therapy and radiographic confirmation of stable disease. Radiographic confirmation of stable disease 4 weeks after completion of radiation therapy is not required unless indicated by neurological examination.

11. All female subjects will be considered to be of childbearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically. For female participants and female partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g. oral contraceptive and condom, intra-uterine device and condom) while on study and for 30 days after the last study treatment. For male participants or male partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g. oral contraceptive and condom, intra-uterine device and condom,) while on study and for three months after the last study treatment.

12. Provision of signed Informed Consent prior to any study related procedure being performed

Exclusion Criteria:

1. Receipt of any other investigational agent within 28 days prior to first administration of AMC303. Investigational monoclonal antibodies must not be given within 6 weeks before treatment start with AMC303.

2. Enrolment in another clinical study with an investigational drug

3. Presence of residual toxicities of CTCAE Grade > 1 after prior anti-tumour therapy within 2 weeks of first treatment with AMC303 with the exception of Grade 3 alopecia and infusion site reactions

4. Severe concurrent illness or psychiatric illness/social situation that would limit compliance with study requirements

5. Anticipation of major surgical procedures within first 4 weeks of first dose

6. Pregnancy or breast-feeding as determined by a serum pregnancy test (ß-HCG) at screening prior to administration of AMC303 and willingness to father a child or to become pregnant

7. Untreated acute infectious disease

8. Patient is known to be suffering from Acquired Immune Deficiency Syndrome (AIDS) or is known to be HIV seropositive without AIDS defining disease

9. Known chronic hepatitis B or C.

10. History of allergic reactions attributed to compounds of similar chemical or biological composition to AMC303.

11. Evidence of any other medical conditions that in the opinion of the investigator may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications

12. Previous malignant disease other than the target malignancy to be investigated within the last 5 years with the exception of basal or squamous carcinoma of the skin or cervical carcinoma in situ

13. Legal incapacity or limited legal capacity

Related Conditions & MeSH terms

• Malignant Solid Tumor
• Neoplasms

Intervention

Drug:
• AMC303
AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways

Locations

Country	Name	City	State
Belgium	Cliniques Universitaires Saint Luc	Brussel
Belgium	Jules Bordet Instiut	Brussels
Spain	Vall d'Hebron Institute of Oncology (VHIO)	Barcelona
Spain	Institut Català d'Oncologia, Hospital Duran i Reynals	L'Hospitalet de Llobregat	Barcelona
Spain	START Madrid-CIOCC, Centro Integral Oncológico Clara Campal	Madiedo
Spain	Hospital Universitario Virgen de la Victoria	Málaga
Spain	Instituto de Investigación Sanitaria INCLIVA, Hospital Clínico de Valencia	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
amcure GmbH

Countries where clinical trial is conducted

Belgium,  Spain, 

References & Publications (1)

Matzke-Ogi A, Jannasch K, Shatirishvili M, Fuchs B, Chiblak S, Morton J, Tawk B, Lindner T, Sansom O, Alves F, Warth A, Schwager C, Mier W, Kleeff J, Ponta H, Abdollahi A, Orian-Rousseau V. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. Gastroenterology. 2016 Feb;150(2):513-25.e10. doi: 10.1053/j.gastro.2015.10.020. Epub 2015 Oct 24. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of AMC303	Number of patients with treatment-related adverse events as assessed by CTCAE v4.0	6 months
Secondary	Pharmacokinetic properties of AMC303 (Cmax)	Determine maximum plasma concentration (Cmax)	2 days
Secondary	Pharmacokinetic properties of AMC303 (AUC)	Determine systemic exposure (AUC) after intravenous infusion	2 days
Secondary	Pharmacokinetic properties of AMC303 (t1/2)	Determine half-life of AMC303 after intravenous infusion	2 days
Secondary	Response rate of treatment with AMC303 in patients with metastatic solid tumors	Determination of the complete response (CR) and partial response (PR) in patients treated with AMC303	12 months

External Links

•   Homepage amcure